Thomas Callahan
Staff
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Background While various reports described the characteristics and catheter ablation strategies for para-Hisian premature ventricular contraction (PVC), the patient population were limited in previous literatures and optimal approach remain unknown. This study sought to comprehensively assess the safety and outcomes of catheter ablation for para-Hisian PVC, with a particular focus on the safety and efficacy of ablation from aortic coronary cusps. Methods A total of 122 para-Hisian PVC cases were retrospectively included in this study. The acute and clinical outcomes of ablation, especially the success rate, the rate of conduction system injury, and the ablation site (right side, left side His bundle (HB) region, and aortic coronary cusp), were analyzed. Results Acute procedural success was achieved in 89 patients (73%). However, long-term clinical success (≥80% reduction of PVC burden) was achieved only in 52% of acute-success cases. Cusp ablation was attempted in 35 patients (31%). Cusp ablation was performed significantly more often in clinical-success cases than clinical-failed cases (38% vs.7% P = 0.005), although ablation from multiple locations was still required. In 28 of 35 cases (80%) who underwent cusp ablation, cusp ablation affected PVC by eliminating, transiently suppressing, or changing morphology. Predictors of successful cusp ablation included earlier activation at the cusp and close anatomical proximity to the earliest site at the HB region. Conduction system injury occurred in 31 cases of the entire cohort, mainly during the HB-region ablation, with only one event during cusp ablation. Conclusion In this large cohort of para-Hisian PVC ablation, an anatomical approach from the adjacent coronary cusp ablation can be considered as an effective and safe strategy. Early local activation and a close anatomical proximity between the earliest para-Hisian site and the coronary cusp region are predictors of ablation success with this approach. What is known Catheter ablation of para-Hisian premature ventricular contraction (PVC) is challenging due to the proximity to the His bundle (HB) and/or potentially intramural sources. Catheter mapping and ablation from multiple sites, including aortic coronary cusps, have been reported as potential alternative approaches, however systematic analyses of the ablation outcome and safety for para-Hisian PVC remain scarce. What the study adds Clinical-success rate of radiofrequency (RF) ablation for para-Hisian PVC was still suboptimal (52%). However, the cases undergoing cusp ablation were associated with a better success rate (85%) than those with direct ablation to the HB region alone (42%), indicating this approach may improve the outcome. The anatomical features, including PVC earliest activation site above the HB or within short distance from the coronary cusp, may predict successful PVC elimination from the coronary cusp. Conduction system injury, including minor forms, occurred in approximately 30% cases during the RF ablation near the HB region, while only one AH prolongation observed during cusp ablation, indicating superior safety of cusp ablation.
Year:
2026
Background Catheter ablation is a first‐line therapy for atrial fibrillation (AF). We evaluated the impact of obstructive sleep apnea (OSA) on arrhythmia and postablation quality‐of‐life outcomes among AF subtypes. Methods Consecutive patients undergoing AF ablation (2013–2022) at a tertiary center were enrolled and assessed for arrhythmia recurrence over 3‐year follow‐up. A subset of patients enrolled in an automated patient‐reported outcomes platform were assessed for quality of life, including Atrial Fibrillation Severity Score and AF burden (AF duration and frequency scores). Results A total of 7020 patients were included: 3380 with paroxysmal AF (PAF) and 3640 with persistent AF (PersAF), of whom 729 and 943 had OSA, respectively (PAF: age, 66.5±10 years [69% men]; PersAF: age, 66.1±9 years [76% men]). Unlike patients with PersAF, those with PAF and OSA had higher AF recurrence (PAF: no OSA=70% versus OSA=64% [ P <0.01]; PersAF: no OSA=57% versus OSA=60% [ P =0.24]). Baseline OSA was independently associated with a 30% increased AF recurrence risk (hazard ratio, 1.30; P <0.001) among patients with PAF, but not among patients with PersAF. Significant improvement in 1‐year postablation quality of life was noted in both groups irrespective of OSA ( P <0.001 for all comparisons): (1) median AF symptom severity (PAF: no OSA 10→2, OSA 12→4; PersAF: 12→4 in both groups); and (2) median AF duration (PAF: 6.25→0 in both groups; PersAF: 10→0 in both groups); median AF frequency (PAF: 6→0 in both groups; PersAF: 9→0 in both groups). Conclusions Baseline OSA was associated with an increased AF recurrence risk in patients with PAF, but not in those with PersAF. Catheter ablation resulted in improvement of quality‐of‐life metrics irrespective of baseline OSA among AF subtypes.
Year:
2025
Introduction Iatrogenic lead perforation is a rare but serious complication of cardiac implantable electronic device (CIED) implantation. Evidence on percutaneous management of subacute or delayed cases remains limited. Methods We retrospectively reviewed 38 patients treated for iatrogenic lead perforation between January 2012 and October 2024. Acute lead perforation cases, which were managed during the implantation procedure, were excluded. Lead removal was performed under imaging guidance in either the electrophysiology (EP) lab or a hybrid operating room (OR) with surgical backup. Clinical presentation, imaging, procedural approach, and outcomes were analyzed. Results Of 38 patients, 25 underwent lead removal in the EP lab and 13 in the OR. The mean age was 67 ± 15 years; 58% were female. Most perforated leads were pacemaker leads (58%), typically involving the right ventricle (72%). Complete removal and reimplantation were achieved in all patients using simple traction with or without a locking stylet. Pericardiocentesis was required in 8% of cases. No major complications or delayed events were observed over a median 16‐month follow‐up. Conclusion Percutaneous removal of perforated leads is feasible and safe in the EP lab when performed by experienced operators. Surgical backup should be readily available given the potential consequences of this complication.
Year:
2025
Aims Anatomical studies have documented a close topographical relationship between the ganglionated plexi (GP) containing parasympathetic inputs to the sinus node (SN) and atrioventricular node (AVN) and the epicardial fat pads (FPs) within the Waterston’s interatrial groove. We aimed to investigate the feasibility and outcomes of a novel anatomical approach to cardioneuroablation (CNA) that targets the atrial areas adjacent to the interatrial FPs identified with intracardiac echocardiography (ICE). Methods and results About 17 patients [37.3 ± 10.2 years, 47% female] undergoing CNA for recurrent vasovagal syncope and documented sinus pauses (n = 13, 76%) and/or AVN block (AVB, n = 4, 16%) were included. The right superior RS-FP containing the RS-GP (target for SN vagal denervation) and the right inferior RI-FP containing the RI-GP (target for AVN vagal denervation) were identified with ICE and reconstructed on a 3D electroanatomic map. At baseline, all patients had provocable sinus pauses/AVB with extracardiac high-frequency vagal stimulation (ECVS). The target FPs could be identified in all patients and were adjacent to septal LA and RA sites covering an average surface area of 3.7 ± 1.4 cm2 and 2.97 ± 1.21 cm2, respectively. A total of 33 ± 15 RF ablations (30–40W, 60 s) were delivered to cover the target LA/RA area. A > 25% shortening of the PP interval was observed within the first 1–2 RF lesions in all cases. After ablation, complete abolition of sinus pauses/AVB response with ECVS was achieved in all patients, and 2 mg of atropine infusion resulted in no PP/PR interval change. After a median follow-up of 12 months (range 4–25 months), 16 patients (94%) remained free of recurrent symptoms (1 patient underwent repeat CNA for recurrent pre-syncope and AVB, 1 patient underwent PPM implant following ECG recording of asymptomatic diurnal AVB). Conclusion An ICE-guided anatomical approach to CNA targeting visible FPs at the Waterston’s groove is a feasible and effective strategy to achieve SN/AVN vagal denervation, with good outcomes at mid-term follow-up.
Year:
2025
Year:
2025
Background The incidence and predictors of pacing‐induced cardiomyopathy (PICM) in patients undergoing attempted left bundle branch area pacing (LBBAP) are unknown. Objective To examine the incidence and predictors of PICM in patients with preserved left ventricular ejection fraction (LVEF) and atrioventricular block (AVB) undergoing attempted LBBAP. Methods The study cohort included consecutive patients undergoing an attempt at LBBAP at the Cleveland Clinic from 2018 until 2022 with preserved LVEF and AVB. PICM was defined as post‐PM LVEF decrease to 5%, > 10% decrease from pre‐PM implantation. Patients who had alternative reasons for a decrease in LVEF during follow‐up were excluded. LBBAP was defined as meeting common criteria for LBBAP and the incidence of PICM was evaluated. Results A total of 173 patients were included. PICM developed in 13/173 (7.5%) of patients at 26 (IQR 7–70) weeks after PM implantation. In total, 12 (6.9%) patients experienced LVEF > 10% decrease. Of 173 patients, 118 (68.2%) patients met criteria for LBBAP. The LBBAP group had a significantly lower incidence of PICM compared with the non‐LBBAP group (log rank p = 0.048). The optimal V6RWPT for predicting PICM was 80 ms and the incidence of PICM increased in proportion to the increase in V6RWPT. In multivariate analysis, non‐LBBA capture (HR: 5.58, 95% CI: 1.46–24.32; p = 0.01) and LVEF at pre‐PM implant per 10% (HR: 0.11, 95% CI: 0.02–0.40; p = 0.0003) were independent predictors for the development of PICM. Conclusion The incidence of PICM with LBBAP in paced patients undergoing PM implant with AVB and preserved LVEF is low. LBBA capture was associated with freedom from PICM.
Year:
2025
Year:
2025
Aims Ventricular tachycardia (VT) non-inducibility in response to programmed ventricular stimulation (PVS) is a widely used procedural endpoint for VT ablation despite inconclusive evidence with respect to clinical outcomes in high-risk patients. The aim is to determine the utility of acute post-ablation VT inducibility as a predictor of VT recurrence, mortality, or mortality equivalent in high-risk patients. Methods and results We conducted a retrospective analysis of high-risk patients (defined as PAINESD > 17) who underwent scar-related VT ablation at our institution between July 2010 and July 2022. Patients’ response to PVS (post-procedure) was categorized into three groups: Group A, no clinical VT or VT with cycle length > 240 ms inducible; Group B, only non-clinical VT with cycle length > 240 ms induced; and Group C, all other outcomes (including cases where no PVS was performed). The combined primary endpoint included death, durable left ventricular assist device placement, and cardiac transplant (Cox analysis). Ventricular tachycardia recurrence was considered a secondary endpoint (competing risk analysis). Of the 1677 VT ablation cases, 123 cases met the inclusion criteria for analysis. During a 19-month median follow-up time (interquartile range 4–43 months), 82 (66.7%) patients experienced the composite primary endpoint. There was no difference between Groups A and C with respect to the primary [hazard ratio (HR) = 1.21 (0.94–1.57), P = 0.145] or secondary [HR = 1.18 (0.91–1.54), P = 0.210] outcomes. These findings persisted after multivariate adjustments. The size of Group B (n = 13) did not permit meaningful statistical analysis. Conclusion The results of post-ablation PVS do not significantly correlate with long-term outcomes in high-risk (PAINESD > 17) VT ablation patients.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (4)
Mina K. Chung
-
Kenneth Mayuga
Founding Director of the Space Health Center
Cleveland Clinic
Pasquale Santangeli
Hospital of the University of Pennsylvania
Tyler Taigen
Electrophysiologist/Director Quality/Associate Section Head
Cleveland Clinic
Make your next move.
Prepare your application
Review drafts before you send them.